152
Participants
Start Date
November 15, 2018
Primary Completion Date
April 8, 2024
Study Completion Date
April 15, 2024
Relacorilant
Relacorilant is supplied as 100 mg capsules for oral dosing.
Placebo
Placebo matched to study drug
Site 47, Vienna
Site 27, Sofia
Site 57, New York
Site 35, New York
Site 38, Orbassano
Site 39, New York
Site 6, Jamaica
Site 8, Albany
Site 19, Pittsburgh
Site 71, Pittsburgh
Site 25, Girona
Site 62, Philadelphia
Site 26, Milan
Site 45, Baltimore
Site 24, Madrid
Site 1, Wilmington
Site 22, Málaga
Site 5, Summerville
Site 14, Atlanta
Site 10, Miami
Site 67, Padua
Site 4, Jackson
Site 23, Seville
Site 17, Columbus
Site 7, Indianapolis
Site 20, Ann Arbor
Site 43, Ancona
Site 41, Chicago
Site 13, St Louis
Site 53, Omaha
Site 2, Metairie
Site 11, Oklahoma City
Site 51, Dallas
Site 65, Houston
Site 56, Shavano Park
Site 3, El Paso
Site 12, Napoli
Site 54, München
Site 21, Phoenix
Site 72, Reno
Site 36, Los Angeles
Site 68, Torrance
Site 49, Würzburg
Site 15, Messina
Site 31, Everett
Site 73, Iași
Site 30, Jerusalem
Site 29, Kfar Saba
Site 28, Petah Tikva
Site 46, Boston
Site 70, Halifax
Site 58, Montreal
Site 69, Tel Aviv
Site 77, Bialystok
Site 40, Roma
Site 16, Roma
Site 34, Rotterdam
Site 37, Chrzanów
Site 59, Krakow
Site 33, Lublin
Site 66, Bucharest
Site 63, Bucharest
Site 64, Bucharest
Site 75, Alicante
Lead Sponsor
Corcept Therapeutics
INDUSTRY